Consider Ferric Citrate in Patients With High Phosphate and Low Iron
August 2015
Ferric citrate (Auryxia, aw-RIK-see-uh) is the first phosphate binder that also increases iron levels in chronic kidney disease patients.
It's an iron-based phosphate binder like sucroferric oxyhydroxide (Velphoro)...but the iron in ferric citrate is absorbed so it can help improve anemia.
Ferric citrate reduces the need for IV iron and erythropoietin-stimulating agents (Epogen, etc). IV iron requirements can drop by about 50% from about 26 to 13 g/week...and ESA doses by about 25% from 7000 to 5300 units/week...through one year of therapy.
Get concise advice on drug therapy, plus unlimited access to CE
Hospital Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote